Back to Search

KATHY MILLER, MD

MD

Hematology & Oncology Physician

NPI: 1649236043IndividualAccepts Medicare

Specialties, Licenses & Credentials

Hematology & Oncology PhysicianPrimary

Internal Medicine — Hematology & Oncology

Code: 207RH0003X

01042335(IN)01042335A(IN)
Medical Oncology Physician

Internal Medicine — Medical Oncology

Code: 207RX0202X

01042335A(IN)

CMS Specialties

PrimaryHEMATOLOGY/ONCOLOGY

Education

OTHER

Class of 1991

Research & Publications (20)

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
PMID 18160686·N Engl J Med·2007
3-trial
A physiologic imaging pilot study of breast cancer treated with AZD2171.
PMID 16397053·Clin Cancer Res·2006
7-preclinical
Can tumor angiogenesis be inhibited without resistance?
PMID 15617473·EXS·2005
6-review
A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer.
PMID 15867237·Clin Cancer Res·2005
3-trial
Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory.
PMID 15692762·Breast Cancer Res Treat·2005
3-trial
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
PMID 15681523·J Clin Oncol·2005
3-trial
A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer.
PMID 15041714·Clin Cancer Res·2004
3-trial
Breast cancer: the role of angiogenesis and antiangiogenic therapy.
PMID 15474336·Hematol Oncol Clin North Am·2004
6-review
The role of ErbB inhibitors in trastuzumab resistance.
PMID 15163843·Oncologist·2004
6-review
Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?
PMID 15084233·Breast Cancer Res·2004
4-observational
A phase II study of 9-nitro-camptothecin in patients with previously treated metastatic breast cancer.
PMID 14707496·Invest New Drugs·2004
3-trial
Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival.
PMID 12853349·Ann Oncol·2003
8-other
E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer.
PMID 12636887·Clin Breast Cancer·2003
8-other
The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era.
PMID 12488288·Ann Oncol·2003
6-review
A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer.
PMID 12181245·Ann Oncol·2002
3-trial
Issues and challenges for antiangiogenic therapies.
PMID 12353823·Breast Cancer Res Treat·2002
6-review
Selection bias in clinical trials.
PMID 15687634·Breast Dis·2001
8-other
Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
PMID 11252888·Oncology (Williston Park)·2001
3-trial
Redefining the target: chemotherapeutics as antiangiogenics.
PMID 11181686·J Clin Oncol·2001
6-review
Primary yolk sac tumor of the rectum.
PMID 11036466·Cancer Invest·2000
5-case

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Via practice · 2 locations total

Address
535 BARNHILL DR, RT 473
INDIANAPOLIS, IN 46202

Locations (2)

Practice Location

535 BARNHILL DR, INDIANAPOLIS, IN
(317) 274-3960

Practice Location

1701 N SENATE BLVD, INDIANAPOLIS, IN
(888) 484-3258

Quick Facts

NPI
1649236043
Entity Type
Individual
Gender
Female
Medicare
Accepted
Specialties
3
Locations
2
Years in Practice
35
Publications
20

Are you this provider?

Claim Your Profile